TG Therapeutics TGTX Cash Flow Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $447.18M+1,812% | $23.38M— | —— | -$223.81M+35.7% | ||
| $59K-13.2% | $68K-67.8% | $211K-30.4% | $303K+7.4% | ||
| $64.67M+52.0% | $42.54M+12.1% | $37.93M-15.0% | $44.65M-27.1% | ||
| —— | —— | $0— | —— | ||
| $1.22M-39.0% | $2M-16.1% | $2.38M+29.0% | $1.84M+60.5% | ||
| $176.44M+126% | $78.09M+52.8% | $51.09M+3,778% | -$1.39M-200% | ||
| —— | $66.85M+81.0% | $36.94M— | —— | ||
| —— | —— | $192K+102% | -$11.01M-169% | ||
| —— | —— | $2.68M— | —— | ||
| —— | —— | —— | -$152K0.0% | ||
| —— | —— | —— | —— | ||
| -$298K+60.5% | -$754K— | $0— | $0— | ||
| $1.75M-8.0% | $1.9M-3.2% | $1.96M-27.7% | $2.72M+43.2% | ||
| —— | -$4.61M— | —— | $0— | ||
| -$2.1M+12.1% | -$2.39M-0.5% | -$2.38M— | —— | ||
| $42.43M— | —— | —— | -$8.39M-199% | ||
| —— | —— | —— | -$176.17M+40.4% | ||
| $214K+376% | $45K— | —— | $14K-96.5% | ||
| $237.5M-23.6% | $310.9M+223% | $96.23M— | —— | ||
| —— | —— | $0— | —— | ||
| $222.24M-28.4% | $310.52M+111% | $146.88M— | —— | ||
| —— | —— | -$50.65M— | —— | ||
| $91.24M+942% | $8.76M— | —— | $0— | ||
| —— | —— | —— | $0-100% | ||
| $0— | $0-100% | $46.3M— | —— | ||
| —— | —— | —— | —— | ||
| -$90.79M-167% | $134.6M+85.1% | $72.71M— | —— | ||
| -$105.78M— | —— | —— | -$196.57M+22.8% | ||
| $24.25M+31.3% | $18.47M+111% | $8.77M— | —— | ||
| $7.88M— | —— | $0— | $0— | ||
| $1.22M-39.0% | $2M-16.1% | $2.38M+29.0% | $1.84M+60.5% | ||
| —— | —— | —— | -$152K0.0% | ||
| -$2.1M+12.1% | -$2.39M-0.5% | -$2.38M— | —— | ||
| $42.43M— | —— | —— | -$8.39M-199% | ||
| —— | —— | $2.68M— | —— | ||
| $6.17M— | $0— | $0— | —— | ||
| $3.79M-45.8% | $6.98M+212% | $2.24M+576% | $331K— | ||
| $1.75M-8.0% | $1.9M-3.2% | $1.96M-27.7% | $2.72M+43.2% | ||
| —— | —— | $0— | —— | ||
| $222.24M-28.4% | $310.52M+111% | $146.88M— | —— | ||
| $91.24M+942% | $8.76M— | —— | $0— | ||
| —— | —— | —— | $0-100% | ||
| $185K-12.7% | $212K0.0% | $212K0.0% | $212K0.0% | ||
| —— | -$304K-169% | -$113K— | —— | ||
| $0— | $0-100% | $1.24M— | $0— | ||
| —— | -$107.55M— | —— | —— | ||
| —— | —— | —— | —— | ||
| $0— | $0-100% | $595K— | $0— | ||
| $7.88M— | —— | $0— | $0— | ||
| —— | —— | —— | -$176.18M+40.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does TG Therapeutics generate?
- TG Therapeutics (TGTX) generated -$95.4M in operating cash flow over the trailing twelve months.
- What is TG Therapeutics's free cash flow?
- After $240.0K of capital expenditures, TG Therapeutics's free cash flow was -$95.6M over the trailing twelve months, down 66.2% year over year.
- Where does TG Therapeutics's cash flow data come from?
- Every line is extracted from TG Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
